NorthWest Biotherapeutics Inc (NWBO)

[biosectinvestor]

Some measures might not about be “approval” based upon survival data, they could rather be about distinguishing the new definition and also understanding the mechanism for larger approval based upon biomarkers later.

Your formalistic view is really out of sync not just with the reforms but also with what broader ends they are likely going after with the trial and the immensely valuable data set they have collected and that they can now create and analyze more broadly to enhance the value of the company and the valuable understanding of this technology and how it works.

You are so incredibly linear in your thinking. It’s really a huge disadvantage for you.